<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03228329</url>
  </required_header>
  <id_info>
    <org_study_id>N-43-2017</org_study_id>
    <nct_id>NCT03228329</nct_id>
  </id_info>
  <brief_title>Validation of Cardiometry in Resuscitation of Patients Undergoing Liver Transplantation</brief_title>
  <official_title>Validation of Electrical Cardiometry in Resuscitation of Patients Undergoing Orthotopic Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      aim of our study to validate electrical cardiometry readings against same readings by&#xD;
      transoesophageal echo. we will validate stroke volume (SV) readings stroke volume&#xD;
      variation(SVV), index of contractility.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction of anaesthesia will be by using propofol (2mg.kg) IV, fentanyl (1-2μg. kg) IV and&#xD;
      atracurium (0.5 mg.kg) IV. Anaesthesia will be maintained with Sevoflurane adjusted between&#xD;
      1-2% in an air ⁄ oxygen mix (FiO2 0.6), fentanyl infusion at 1-2 μg.kg/h and atracurium&#xD;
      infusion at 0.5 mg.kg/ h. Mechanical ventilation will be provided by using a Dräger&#xD;
      anaesthesia machine (Dräger Primus®, Germany) using a tidal volume of 6-8 ml.kg with the&#xD;
      respiratory rate adjusted to maintain the PaCO2 between 4-4.6 kilopascal (kPa) and positive&#xD;
      end expiratory pressure (PEEP) of 5 cmH2O. All patients will be monitored for five lead ECG,&#xD;
      peripheral oxygen saturation, noninvasive and invasive arterial blood pressure, temperature,&#xD;
      end-tidal carbon dioxide tension, hourly urinary output, and central venous pressure (CVP). A&#xD;
      7-Fr triple lumen CVP catheter (Arrow International Inc, Reading, PA, USA) will be inserted&#xD;
      into the right internal jugular vein.&#xD;
&#xD;
      All patients will receive 6ml /kg/h Ringer acetate solution as a maintenance intraoperative&#xD;
      fluid. If SVV is more than 15%, the patient will be considered as fluid responder and will&#xD;
      receive a 250-ml bolus of albumin 5% to maintain SVV ≤15%. Blood transfusion will be given&#xD;
      based on a hemoglobin level (&lt; 7 g/dl). Norepinephrine will be administered if the mean&#xD;
      arterial pressure was less than 70 mmHg. Epinephrine will be administered if mean arterial&#xD;
      blood pressure was less than 70 mm Hg and the cardiac index was less than 2.5 L/min/m2&#xD;
      despite sufficient volume infusion, to maintain a target cardiac index of 2.5-3.0 L/min/m2&#xD;
&#xD;
      Electrical cardiometry (EC) Examination:&#xD;
&#xD;
        1. ECG electrodes will be placed on the bare skin of patients in the following positions:&#xD;
&#xD;
             1. On the left neck below the ear;&#xD;
&#xD;
             2. Directly above the midpoint of the left clavicle;&#xD;
&#xD;
             3. Along the left mid-axillary line at the level of the xiphoid process;&#xD;
&#xD;
             4. Two inches caudal from the third electrode.&#xD;
&#xD;
        2. Patient characteristics of sex, age, height and weight will be entered into the monitor.&#xD;
&#xD;
        3. Clocks on the EC and trans esophageal echo (TEE) machine will be synchronized prior to&#xD;
           data collection.&#xD;
&#xD;
        4. The EC monitor will be programmed to capture moving averages of variables based on the&#xD;
           previous 10 cardiac cycles and to record those averages every10 s.&#xD;
&#xD;
        5. Only EC data with a signal quality index (SQI) of &gt;70 will be included in the analysis.&#xD;
&#xD;
      Echo Examination:&#xD;
&#xD;
        1. A single LVOT diameter will be measured for each patient as the distance between the&#xD;
           inﬂection points at the base of the aortic valve cusps from the left ventricle long axis&#xD;
           view during systole.&#xD;
&#xD;
        2. Assuming a circular cross section, the LVOT area will be calculated from the LVOT&#xD;
           diameter as:&#xD;
&#xD;
           π X (LVOT diameter/ 2)2 = (LVOT diameter)2 X 0.785&#xD;
&#xD;
        3. Pulse wave Doppler sampling cursor will be placed in the middle of the LVOT immediately&#xD;
           proximal to the aortic valve in 5 chamber deep transgastric view.&#xD;
&#xD;
        4. The sonographer manually will trace the velocity-time envelope.&#xD;
&#xD;
        5. SV values will be identified for 10 cycles and averaged to obtain SV-Doppler max and&#xD;
           SV-Doppler min. The mean SV (SV-Doppler mean) will be calculated as (SV-Doppler max -&#xD;
           SV-Doppler min)/2.&#xD;
&#xD;
        6. SVV-Doppler will be calculated as (SV-Doppler max - SV-Doppler min)/SV-Doppler mean.&#xD;
&#xD;
        7. Peak aortic velocity, time to peak and mean acceleration will be calculated.&#xD;
&#xD;
      Mini Fluid challenge:&#xD;
&#xD;
        1. Mini fluid challenge will be done by 150 cc crystalloid over 1 min&#xD;
&#xD;
        2. 2 sets of measurement of SV and SVV will be obtained&#xD;
&#xD;
             1. The first set of measurement will be obtained before fluid challenge.&#xD;
&#xD;
             2. The second set will be obtained immediately after fluid challenge. Other data will&#xD;
                be recorded as;heart rate (HR), systolic BP, Diastolic BP, mean BP, CVP and pulse&#xD;
                pressure variation (PPV)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2017</start_date>
  <completion_date type="Actual">September 20, 2018</completion_date>
  <primary_completion_date type="Actual">September 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stroke volume</measure>
    <time_frame>5 minutes after reperfusion.</time_frame>
    <description>record stroke volume assessed by noninvasive cardiometry and TEE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>stroke volume</measure>
    <time_frame>15 minutes after dissection phase.</time_frame>
    <description>record stroke volume assessed by noninvasive cardiometry and TEE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>stroke volume variation</measure>
    <time_frame>5 minutes after reperfusion.</time_frame>
    <description>record stroke volume assessed by noninvasive cardiometry and TEE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke volume variation</measure>
    <time_frame>15 minutes after dissection phase</time_frame>
    <description>record stroke volume variation assessed by noninvasive cardiometry and TEE</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>cardiometry</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluid boluses</intervention_name>
    <description>fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations</description>
    <arm_group_label>cardiometry</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA II to IV patients with end-stage liver disease&#xD;
&#xD;
          -  patients undergoing orthotopic living donor liver transplantation&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acute fulminant liver failure&#xD;
&#xD;
          -  age &lt; 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ahmed mohamed mokhtar, M.D</last_name>
    <role>Study Director</role>
    <affiliation>kasralainy faculty of medicine, Cairo university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kasr Alainy Hospital , Faculty of Medicine</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Bechstein WO, Neuhaus P. [Bleeding problems in liver surgery and liver transplantation]. Chirurg. 2000 Apr;71(4):363-8. Review. German.</citation>
    <PMID>10840602</PMID>
  </reference>
  <reference>
    <citation>Rossi G, Langer M, Maggi U, Reggiani P, Caccamo L, Gatti S, Paone G, Vannelli A, Prato P, Doglia M, Melada E, Latham L, Fassati LR. Veno-venous bypass versus no bypass in orthotopic liver transplantation: hemodynamic, metabolic, and renal data. Transplant Proc. 1998 Aug;30(5):1871-3.</citation>
    <PMID>9723316</PMID>
  </reference>
  <reference>
    <citation>Bulkley GB. Reactive oxygen metabolites and reperfusion injury: aberrant triggering of reticuloendothelial function. Lancet. 1994 Oct 1;344(8927):934-6. Review.</citation>
    <PMID>7848422</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 13, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>December 21, 2018</last_update_submitted>
  <last_update_submitted_qc>December 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Mohamed Elayashy Mohamed Ahmed Hassan</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <keyword>cardiometry</keyword>
  <keyword>stroke volume</keyword>
  <keyword>liver transplantation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

